IN8bio (INAB) Action Cours

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2020-11-12. The company is focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead product candidates are in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. The company is also focused on patient enrollment in the Company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. Its DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types.